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The terms “AT1”- and “AT2”-receptor were confused in the
introduction of our article (1). Unfortunately, some corrections
that we had indicated in the galley proofs were not performed by
the publisher, and instead, additional errors were introduced (page
1787, right column, second paragraph, lines 3 and 8: AT1 should
have read AT2; and line 11: AT2 should have read AT1). An
erratum was published in JACC 33(2), 1999.
In contrast with the remark in the letter of Drs. Jugdutt and
Moudgil, the term “AT2” on page 1792, left column, line 6, is
correct, because the effect of AT1-receptor blockade by candesar-
tan was lost in the presence of AT2-receptor blockade by
PD123319 (1).
We apologize for having overlooked the study of Ford et al.,
published in the Canadian Journal of Cardiology (2). However, it is
difficult to retrieve articles not listed in Current Contents.
Data on hemodynamics, regional myocardial function and blood
flow during reperfusion following 90 min low-flow ischemia in our
porcine model have been published previously, and have indicated
the absence of a “no-reflow” phenomenon (3). Also, the
relationship between infarct size and subendocardial blood flow
at 5 min ischemia is not different from the relationship between
infarct size and blood flow at 85 min ischemia in this model (4).
A relationship between infarct size and the area at risk was not
reported in the present study (1), because—as previously pub-
lished studies of rats (5), rabbits (6) and dogs (5)—we find no
such relationship.
We do not share the understanding of Drs. Jugdutt and
Moudgil that the reduction of infarct size achieved by AT1-
receptor blockade (1) is due to a vascular mechanism, whereas the
beneficial effects of AT2-receptor blockade on the postischemic
recovery of contractile function (7) are of nonvascular origin. In
fact, in both studies, antagonists of the AT1- or AT2-receptor were
administered from the vascular site, and no distinction was made
for a vascular or myocardial site of the AT-receptors involved in
the observed cardioprotection.
We do, however, agree with Drs. Jugdutt and Moudgil that it is
important to study the cardioprotective effects of AT1-receptor
blockade in patients and to better define a patient population that
may particularly benefit from such treatment.
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Additive Effects of Simvastatin and
Hormone Replacement Therapy in
Hypercholesterolemic Postmenopausal Women
Sbarouni et al. (1) reported in the November 1 issue of the Journal,
that hormone replacement therapy combined with simvastatin
could exert beneficial effects on plasma lipids in hypercholester-
olemic postmenopausal women. The study was randomized and
placebo-controlled and included 16 postmenopausal women. Re-
cently, we have documented that in a similar population, 10 mg
simvastatin combined with 0.625 mg estrogen and 2.5 mg
medroxyprogesteron acetate daily could affect serum lipid levels
more favorably than simvastatin 10 mg alone (2). The study was
not controlled, but did include 50 patients in each treatment arm,
and had a follow-up period of six months. The mean percent
reduction in total cholesterol and LDL cholesterol and the
mean percent increase in serum HDL cholesterol concentra-
tions were also significantly greater in the combination group
both at three and six months (Table 1). Furthermore, signifi-
cantly more patients in the combination group attained their
target treatment goals dictated by the U.S. National Cholesterol
Education Program Adult Treatment Panel II Guidelines.
The findings of both studies point out an additive effect of
simvastatin and hormone replacement therapy, and suggest that
hormone replacement therapy could be a substantial component
aiding the management of hypercholesterolemia in postmeno-
pausal women when balanced for other costs and possible related
risks.
Table 1. Effects of Simvastatin and Hormone Replacement
Therapy on Lipid Profile
Mean % change
(at 6 months)
Simvastatin
10 mg 1 HRT
Simvastatin
10 mg alone
Total cholesterol 14.6 6 7.7* 11.3 6 7.4
LDL cholesterol 23.3 6 9.7† 15.8 6 12.3
HDL cholesterol 21.3 6 15.2† 11.1 6 12.5
Triglycerides 9.8 6 15.3 7.3 6 9.0
HRT 5 hormone replacement therapy; 0.625 mg estrogen 1 2.5 mg medroxypro-
gesteron acetate daily.
*p , 0.05, †p , 0.005.
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Aortic Debris and
Coronary Guiding Catheters
I read with interest the recent article by Keeley and Grines
regarding scraping of aortic debris by coronary guiding catheters.
This has been a problem for all interventional cardiologists, and it
is rewarding to see this issue addressed in a quantitative fashion in
this publication. We have had experiences similar to those of the
authors in identifying atheromatous debris, particularly with the
use of left coronary guiding catheters.
There are several issues not addressed in the article that I believe
deserve mention. First, it has been our experience that the larger
bore guide catheters cause release of more atheromatous debris.
There seems to be a noticeable increase when switching from 8 fr
to 9 fr guides.
Second, a method of minimizing or avoiding the scraping of
aortic debris is the insertion of an obturator inside the guiding
catheter. The one that we commonly use is a DVI introducing
catheter, which is 110 cm long. For a 9-fr guide, we use a 7-fr
obturator. For an 8 fr guide, we use a 6 fr obturator. An
alternative would be the use of a 110 or 125 cm diagnostic
multipurpose catheter to serve as an obturator. With the use of
the obturator, there is a smooth transition from the wire to the
guiding catheter and thus, the amount of aortic debris is
significantly reduced.
In our experience, the most voluminous release of debris is
during renal artery stenting procedures. Many of these patients
have diffuse aortic atherosclerosis and the shape of the renal artery
guide catheters is extremely conducive to scraping of aortic debris.
Again, we have found that the use of obturators significantly
minimizes this effect.
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In our practice, the trend has been to downsize guiding catheter
size as well as femoral sheath size. From the start of this
prospective analysis, newer balloon and stent designs have made
the use of 6 and 7 F guiding catheters technically feasible and
desirable. Only 80 catheters of the 1,000 catheters evaluated were
9 or 10 F in size (0.08%); most were 8 F. When this small
subgroup was analyzed, there was no statistically significant dif-
ference in the amount of debris collected. This may be primarily a
result of a small sample size.
We believe that most aortic scraping occurs due to catheter
shape, particularly the extent of the secondary bend. This is
perhaps why in your practice Krainin et al. have noted increased
debris collection with the use of renal artery guiding catheters.
Properly sized obturators not only fill the lumen, but also
straighten the curves of the guiding catheter making it less likely to
scrape the aorta. Although we routinely use obturators with large
bore (10 F) guiding catheters, we do not do so with 8 and 9 F
guiding catheters. It is unclear whether the use of obturators may
actually hinder the exit of the debris from the guiding catheter and
lead to increased risk of embolization.
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ST Elevation Secondary
to Microvascular Dysfunction
Murakami and colleagues (1) recently described three cases of
spontaneous ST elevation in patients with angiographic normal
coronary arteries and implicated microvascular dysfunction as the
cause of the transmural ischemia. This hypothesis is valid if large
vessel coronary spasm has been adequately excluded. Two aspects
of their report require further clarification before this can be
satisfied (1). The serial electrocardiograms (ECGs) that reported
ST elevation also demonstrated T wave inversion, an early ECG
sign of reperfusion. Thus, the angiographic snapshot may have
unfortunately been taken after resolution of the transient coronary
spasm (2). The acetylcholine provocation test used to exclude
coronary spasm appears to have been performed after high-dose
intracoronary nitrates, thereby potentially inhibiting the spastic
response. If these details have been addressed, the findings of
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